Compare Occidental Petroleum Corporation (OXY) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs ResMed Inc. — how do they compare? Occidental Petroleum Corporation trades at $60.07 (market cap $58.19B), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: Occidental Petroleum Corporation is the larger of the two by market cap, and Occidental Petroleum Corporation pays the higher dividend (1.92%). Which is the better fit depends on your goals — on Pluang, investors hold Occidental Petroleum Corporation for 92 Days and ResMed Inc. for 51 Days on average.
| OXY | RMD | |
|---|---|---|
Market Cap | $58.19B | $31.78B |
Volume | 7,092,290 | 1,128,382 |
Sector | Energy | Health |
52-Week High | $66.24 | $277.88 |
52-Week Low | $38.92 | $182.82 |
Typical Hold Time | 92 Days | 51 Days |
Enterprise Value | $76.95B | $31.14B |
Dividend Yield | 1.92% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $60.28, up 3.34% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by a consensus price target of $71.40, indicating potential upside. Recent news highlights Goldman Sachs' upgrade to Buy, citing cash flow targets and debt reduction. Revenue has declined from $36.6B in 2022 to $21.6B in 2025, but net income margin remains healthy at 30.32%, and the company maintains a solid balance sheet with manageable debt levels.
OXY presents a favorable risk-reward profile with analyst optimism and operational efficiency, though exposure to oil price volatility and competitive pressures pose risks. The upcoming Q3 2026 earnings report on November 9 is a key catalyst. Institutional sentiment is positive, with 52% of analysts rating it Buy. Investors should weigh the stock's valuation appeal against macroeconomic headwinds affecting the energy sector.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
